Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05760300 · ClinicalTrials.gov registry record · Phase 1
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
A Phase 1 study of Chronic Hepatitis D Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 9
- Study locations
NCT05760300: Completed Phase 1 study of Chronic Hepatitis D Infection, sponsored by Gilead Sciences.
NCT05760300 is a Phase 1 study of Chronic Hepatitis D Infection that has completed, run by Gilead Sciences. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). The trial reports 9 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05760300, a Phase 1 study of Chronic Hepatitis D Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 9
- Study locations
Study Summary
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
Primary Outcome
AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state at Day 6.
Conditions Studied
Interventions
- DRUG Bulevirtide (BLV)
Study Locations (9)
Florida
- Velocity Clinical Research, New Smyrna Beach - Edgewater
- Clinical Pharmacology of Miami, LLC - Miami
- Advanced Pharma CR, LLC - Miami
- Panax Clinical Research - Miami Lakes
- Floridian Clinical Research, LLC - Miami Lakes
- Global Clinical Professionals Research - St. Petersburg
- Genesis Clinical Research, LLC - Tampa
Massachusetts
- Massachusetts General Hospital - Renal Associates Clinic - Boston
Minnesota
- Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2024-07-23 |
| Phase | Phase 1 |
What the finished NCT05760300 record still lists
NCT05760300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Chronic Hepatitis D Infection appearing as the primary indexed condition, and to 1 intervention - of which Bulevirtide (BLV) is the first listed.
NCT05760300 lists 9 locations in 3 states (Florida, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05760300 about?
NCT05760300 is a clinical study titled "A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function". The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with norma...
What is the current status of trial NCT05760300?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-03-15. Estimated completion is 2024-07-23.
What conditions does trial NCT05760300 study?
This clinical trial studies the following conditions: Chronic Hepatitis D Infection.
What interventions are being tested in trial NCT05760300?
The interventions under investigation include: Bulevirtide (BLV) (DRUG).
Who is sponsoring clinical trial NCT05760300?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05760300 being conducted?
This trial has 9 study locations across Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis D Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05760300's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI